CAS: 1792999-26-8

NCB-0846

Applications cis-4-​[[2-​(1H-​Benzimidazol-​6-​ylamino)​-​8-​quinazolinyl]​oxy]​-​cyclohexanol inhibits Traf2 and Nck-interacting protein kinase (TNIK). TNIK is involved with Canonical Wnt/b-catenin signalling, which has regulatory roles in maintaining intestinal stem cells and aberration in this pathway has been implicated in colorectal carcinogenesis. TNIK is a therapeutic target. References Masuda, M., et al.: Nat Commun. 7, 12586 (2016); Masuda, M., et al.: Pharmacol. Ther. 156, 1 (2017);

Cis-4-((2-((1H-Benzo[D]Imidazol-6-Yl)Amino)Quinazolin-8-Yl)Oxy)Cyclohexanol

NCB-0846 is an orally active TNIK inhibitor (IC50: 21 nM).

Cis-4-[[2-(1H-benzimidazol-6-ylamino)-8-quinazolinyl]oxy]-cyclohexanol is a ligand that binds to the coxsackievirus and adenovirus receptor (CovR) and blocks its function. The CovR protein is expressed on the surface of cells in the heart, lungs, and other tissues. Cis-4-[[2-(1H-Benzimidazol-6-ylamino)-8-quinazolinyl]oxy]-cyclohexanol is a temporary antiviral agent that has been synthesized to evaluate its potential as an antiviral drug for use during a pandemic. The synthesized compound has been evaluated by analytical methods such as NMR and mass spectroscopy. These evaluations have shown that cis-4-[2-(1H benzimidazol 6 ylamino)-8 quinazolinyl]